Chlorproguanil/dapsone

Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone,^[1] which act synergistically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.^[2]

Chlorproguanil/dapsone

Combination of
Chlorproguanil	Antimalarial drug
Dapsone	Antibiotic
Legal status
Legal status	Withdrawn
Identifiers
CAS Number	209665-78-1